VEGFC in relation to OS and EFS in adult AML. Kaplan-Meier plots show the OS (A) and EFS (B) of adult patients with AML subgroups with high (n = 262) versus low (n = 262) VEGFC expression. (C-D) Evaluation of the effect of VEGFC on OS and EFS among patients with cytogenetically intermediate-risk AML (n = 331). First, within the 331 patients with cytogenetically intermediate-risk AML the association between VEGFC expression and survival was evaluated with the use of tertiles of VEGFC expression. Because the risks in the second and third tertile were comparable (data not shown), the first versus the combination of the second and third VEGFC tertiles were compared with regard to OS and EFS. Kaplan-Meier plots show the OS (C) and EFS (D) in patients with cytogenetically intermediate risk AML with high (ie, second and third tertiles combined) versus low (ie, first tertile) transcript levels of VEGFC. Intermediate cytogenetic risk is defined in “Patients.”